Viridian Therapeutics, Inc.
DE ˙ DB ˙ US92790C1045
14,00 € ↑0,40 (2,94%)
2026-06-04
AKTIENPREIS
SecurityDE:1S1 / Viridian Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership128,358 shares
Latest Disclosed Value $ 1,794,444
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 4.16% increase in ownership of 1S1 / Viridian Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 128,358 shares of Viridian Therapeutics, Inc. (DE:1S1) valued at $1,555,057 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 123,234 shares of Viridian Therapeutics, Inc.. This represents a change in shares of 4.16% during the quarter. The current value of the position is $1,797,012 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Viridian Therapeutics EC US92790C1045 128,358 5,124 4.16 1,794 8.01 0.0403
2025-05-28 2025-03-31 NP Viridian Therapeutics EC US92790C1045 123,234 0 0.00 1,661 -29.68 0.0398
2025-02-25 2024-12-31 NP Viridian Therapeutics EC US92790C1045 123,234 -702 -0.57 2,362 -16.21 0.0516
2024-11-26 2024-09-30 NP Viridian Therapeutics EC US92790C1045 123,936 31,217 33.67 2,820 133.75 0.0533
2024-08-26 2024-06-30 NP Viridian Therapeutics EC US92790C1045 92,719 5,536 6.35 1,206 -20.97 0.0246
2024-05-28 2024-03-31 NP Viridian Therapeutics EC US92790C1045 87,183 9,672 12.48 1,527 -9.60 0.0319
2024-02-26 2023-12-31 NP Viridian Therapeutics EC US92790C1045 77,511 7,237 10.30 1,688 56.59 0.0360
2023-11-28 2023-09-30 NP Viridian Therapeutics EC US92790C1045 70,274 -2,928 -4.00 1,078 -38.08 0.0281
2023-08-25 2023-06-30 NP Viridian Therapeutics EC US92790C1045 73,202 11,860 19.33 1,741 11.60 0.0413
2023-05-26 2023-03-31 NP Viridian Therapeutics EC US92790C1045 61,342 2,900 4.96 1,561 -8.61 0.0416
2023-02-24 2022-12-31 NP Viridian Therapeutics EC US92790C1045 58,442 13,430 29.84 1,707 84.94 0.0470
2022-11-25 2022-09-30 NP Viridian Therapeutics EC US92790C1045 45,012 5,144 12.90 923 100.22 0.0264
2022-08-25 2022-06-30 NP Viridian Therapeutics EC US92790C1045 39,868 39,868 461 0.0127
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.